The impact of adjuvant aripiprazole on olanzapine- induced metabolic adverse effects in schizophrenic patients: a Systematic Review
DOI:
https://doi.org/10.22024/UniKent/03/ajpp.1355Resumen
Abstract
Background: Olanzapine is a second-generation atypical antipsychotic drug which is commonly used in the treatment of psychotic disorders such as schizophrenia. It has been associated with metabolic adverse effects such as, weight gain, hyperglycaemia, dyslipidemia and this has been shown to contribute to the reduction of life expectancy of schizophrenic patients. It has been suggested that adjunctive aripiprazole (another atypical antipsychotic) reduces some of the metabolic adverse effects caused by olanzapine. This systematic review aimed to assess whether adjunctive aripiprazole is effective at reducing metabolic adverse effects induced by olanzapine.
Methods: A systematic review was conducted and due to heterogeneity in the data, a narrative synthesis was completed. A systematic search strategy was developed, recorded, and applied to multiple academic search engines. Using the PRISMA flow diagram, the literature search found a total of 853 results with final inclusion of 7 research articles. Based on a specific inclusion and exclusion criteria, a wide range of study designs were included in the review such as randomised control trials (RCTs), open label trials and case series. Key outcomes were identified which included: glucose levels, lipid profile (which included triglycerides as well as HDL, LDL, and total cholesterol), body weight, BMI and waist circumference. The results were recorded and analysed using narrative synthesis, and conclusions were drawn based on the results reported.
Results: Statistically significant decreases in fasting triglycerides were consistent across multiple studies, supporting the hypothesis that aripiprazole may counteract some of the metabolic adverse effects of olanzapine. Adjunctive aripiprazole shows potential weight loss benefits, with some studies reporting significant reductions in weight and BMI, while one other found no meaningful change. However, this may be a dose dependent outcome, as the study that found no significant change in weight used a substantially lower dose of aripiprazole compared to other studies. Effects on cholesterol and fasting glucose showed non statistically significant reductions and others showed minimal or no impact. Psychiatric symptom control remained stable in most studies, suggesting that aripiprazole does not negatively affect schizophrenia symptoms while potentially providing metabolic advantages.
Conclusions: Adjunctive aripiprazole had variable effects on metabolic parameters in patients on olanzapine therapy, however reductions in triglycerides appeared consistent among the majority of the data and some studies reported significant weight loss. This highlighted that aripiprazole does have some effect in reducing metabolic adverse effects caused by olanzapine. However, there are many possible factors that could influence the metabolic changes shown. This highlights a need for further research and investigations, investigations that will address the gaps in the current research, such as longer randomised control trials (RCTs) with more participants and more information regarding effective dose response.
Keywords: Adjunctive aripiprazole | Olanzapine | Schizophrenia | Metabolic adverse effects
a Stephen Simmons, 4th Year Medical Student, Kent and Medway Medical School, Canterbury, United Kingdom
bDr Soban Sadiq, Senior lecturer, Kent and Medway Medical School, Canterbury, United Kingdom
Main contact email: s.simmons2577@kmms.ac.uk
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
AJPP requests that, as the creator(s)/author(s) of the manuscript you are submitting, that you assign certain rights to the manuscript to the AJPP in exchange for undertaking to publish the article in electronic form and, in general, to pursue its dissemination throughout the world. The rights the AJPP requests are:
- The right to publish the article in electronic form or in any other form it may choose that is in keeping with its role as a scholarly journal with the goal of disseminating the work as widely as possible;
- The right to be the sole publisher of the article for a period of 12 months;
- The right to make the article available to the public within a period of not more than 24 months, as determined by relevant journal staff of the AJPP;
- The right to grant republication rights to itself or others in print, electronic, or any other form, with any revenues accrued to be shared equally between the author(s) and the journal;
- The right to administer permission to use portions of the article as requested by others, seeking recompense when the AJPP sees it as warranted;
- The right to seek or take advantage of opportunities to have the article included in a database aimed at increasing awareness of it;
- As the author(s), the AJPP wishes you to retain the right to republish the article, with acknowledgement of the AJPP as the original publisher, in whole or in part, in any other pbulication of your own, including any anthology that you might edit with up to three others;
- As the author(s), the AJPP wishes you to retain the right to place the article on your personal Web page or respository of your university or institution. The AJPP askes that you include this notice: A fully edited, peer-reviewed version of this article was first published by the Advanced Journal of Professional Practice, <Year>, <Volume>, <Issue>, <Page Numbers>.
- You retain the right to unrestricted use of your paper for yourself or for your own teaching purposes.
BY AGREEING TO THE FOREGOING, YOU CONFIRM THAT THE MANUSCRIPT YOU ARE SUBMITTING HAS NOT BEEN PUBLISHED ELSEWHERE IN WHOLE OR IN PART, AND THAT NO AGREEMENT TO PUBLISH IS OUTSTANDING.
SHOULD THE ARTICLE CONTAIN MATERIAL WHICH REQUIRES WRITTEN PERMISSION FOR INCLUSION, YOU AGREE THAT IT IS YOUR OBLIGATION IN LAW TO IDENTIFY SUCH MATERIAL TO THE EDITOR OF THE AJPP AND TO OBTAIN SUCH PERMISSION. THE AJPP WILL NOT PAY ANY PERMISSION FEES. SHOULD THE AJPP BE OF THE OPINION THAT SUCH PERMISSION IS NECESSARY, IT WILL REQUIRE YOU TO PURSUE SUCH PERMISSSION PRIOR TO PUBLICATION.
AS AUTHOR(S), YOU WARRANT THAT THE ARTICLE BEING SUBMITTED IS ORIGINAL TO YOU.
Provided the foregoing terms are satisfactory, and that you are in agreement with them, please indicate your acceptance by checking the appropriate box and proceed with your submission.
